Иммуногенные и защитные свойства рекомбинантного аденовируса человека 5-го серотипа, экспрессирующего ген гликопротеина G вируса бешенства вакцинного штамма РВ-97

Introduction. Rabies is an acute infectious disease common to both humans and animals. To prevent the disease before contact with the pathogen, pre-exposure prophylactic vaccination (PrEP) of risk groups is used. The classic inactivated culture anti-rabies vaccines are used for immunization of risk groups in Russia. These vaccines are highly effective, but can cause severe adverse reactions and requires a multiple administration. Therefore, it is relevant to develop new safe rabies vaccines to achieve a protective effect with a single administration. The aim of our study was to create replication-defective recombinant human adenovirus serotype 5, that carries the gene for glycoprotein G rabies virus, and to study its protective and immunogenic properties in immunizing laboratory mice. Material and methods. Recombinant adenovirus was obtained using the kit AdEazy Adenoviral vector system (Stratagen, USA). To evaluate the protective properties and immunogenicity of Ad5-RV97 BALB/c mice were immunized once intramuscularly. The humoral immune response was studied using the fluorescent virus neutralization reaction, the T-cell response using the ELISPOT method. Results. Recombinant adenovirus Ad5-RV97 was 100 % protection against rabies viruses. Within 14 days after immunization, high level of virus-neutralizing antibodies was reported, which continue to grow up until day 42 after immunization. Significant level of splenocytes (both CD4⁺- and CD8⁺-cells) producing IFN-γ in response to antigen stimulation was detected. Conclusion. The data obtained allow us to consider Ad5-RV97 as the basis for creating a candidate rabies vaccine, which can be used to treat various risk groups.